Catastrophic asparaginase-induced cerebral and systemic thrombosis in a young female with T-cell lymphoblastic lymphoma: A case report & literature review [0.03%]
一例T细胞淋巴母细胞淋巴瘤患者发生植物血凝素致脑及全身血栓形成的病例报告和文献回顾
Shihab Ahmed Ibrahim Ahmed,Amr Suliman AlHanbali
Shihab Ahmed Ibrahim Ahmed
Asparaginase is a cornerstone in the treatment of acute lymphoblastic leukemia (ALL) and its variant, T-cell lymphoblastic lymphoma (T-LBL), particularly in adolescents and young adults (AYA). However, its use is associated with a significa...
Real-World Efficacy and Safety of Gemtuzumab Ozogamycin (GO) and 3 + 7 regimen in fit newly diagnosed Acute Myeloid Leukemia (AML) patients. A Retrospective multicenter study of "Rete Ematologica Pugliese" (REP) [0.03%]
有关适应人群的急性髓系白血病患者的真实世界疗效及安全性：吉妥珠单抗奥唑米星与3+7方案的回顾性多中心研究（意大利普利亚血液学网络）
M Dargenio,C Buquicchio,D Pastore et al.
M Dargenio et al.
Gemtuzumab Ozogamicin, a monoclonal antibody targeting CD33, linked to calicheamicin, is approved in combination with "3 + 7″ for the treatment of patients with de novo CD33 positive AML. The aim of study was to evaluate the outcome of pat...
Impact of non-coding RNAs on resistance to imatinib in chronic myelogenous leukemia [0.03%]
非编码RNA对慢性髓性白血病伊马替尼耐药的影响
Fatemeh Ensafi Talemi,Soudeh Ghafouri-Fard
Fatemeh Ensafi Talemi
Imatinib is approved as the first-line treatment for newly diagnosed chronic myelogenous leukemia (CML). In spite of profound response in the majority of patients, resistance occurs in a subgroup of CML cases. Recently, it has been demonstr...
Characteristics of BCR::ABL1 kinase domain mutations in Vietnamese chronic myeloid leukemia patients [0.03%]
越南慢性粒细胞性白血病患者BCR::ABL1激酶结构域突变的特点
Phu Chi Dung,Huynh Duc Vinh Phu,Cao Van Dong et al.
Phu Chi Dung et al.
Background: BCR::ABL1 kinase domain (KD) mutations represent a common cause of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia (CML) patients. The frequency and pattern of KD mutations differ among po...
Case report: Experience of a rare case of primary acute mast cell leukemia [0.03%]
个例报道：一例罕见首发急性mast细胞白血病的经验报告
Zhijuan Pan,Ying Zhang,Yanru Guo et al.
Zhijuan Pan et al.
Backgrounds: Mast cell leukemia (MCL) is a rare and aggressive form of systemic mastocytosis with a poor prognosis. Understanding the different therapeutic responses to corticosteroids in MCL is crucial for improving pati...
Pharmacokinetics and outcome of high-dose melphalan followed by autologous stem cell transplantation in dialysis-dependent patients with multiple myeloma [0.03%]
依赖透析的多发性骨髓瘤患者接受自体干细胞移植之前高剂量美法仑的药代动力学和转归情况
Rabea Mecklenbrauck,Bernhard M W Schmidt,Heike Bähre et al.
Rabea Mecklenbrauck et al.
High-dose melphalan followed by autologous stem cell transplantation (ASCT) remains the standard of care for fit patients with multiple myeloma (MM). However, individuals who are dependent on hemodialysis are frequently excluded from ASCT. ...
Involvement of the central nervous system in relapsed T-cell lymphoma: insights from four case studies [0.03%]
复发性T细胞淋巴瘤中枢神经系统受累的四例分析
Radu Chiriac,Lucile Baseggio
Radu Chiriac
CNS involvement in T-cell lymphoma is rare, with a 2-6 % risk of relapse. This report presents four cases of CNS relapse in aggressive T-cell lymphomas, including PTCL NOS, AITL, ALCL ALK (-), and ENKTCL. Patients experienced severe neurolo...
Nivolumab for relapsed and refractory classical Hodgkin lymphoma: retrospective single center analysis [0.03%]
尼伏单抗治疗复发和难治性经典霍奇金淋巴瘤的回顾性单中心分析
Magdalena Witkowska,Mikołaj Malicki,Weronika Marcinkowska et al.
Magdalena Witkowska et al.
With the introduction of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) and radiation combined, the prognosis of Hodgkin lymphoma (HL) has significantly improved, with 5-year overall survival of around 90 %. While the lymphoma ...
Selinexor combination with decitabine and half-dose CMG (Cytarabine+ Mitoxantrone+G-CSF) in Patients with refractory/relapsed acute myeloid leukemia (AML) previously exposed to Venetoclax: a single-center retrospective study [0.03%]
塞利尼索联合地西他滨及减量CM(G方案)(阿糖胞苷+米托蒽醌+G- CSF)治疗既往接受过维奈克拉治疗的复发/难治急性髓系白血病患者的单中心回顾性研究
Zi-Yu Zhao,Xiao-Lei Zhang,Ying Zhan et al.
Zi-Yu Zhao et al.
Corrigendum to "First-line therapy with daratumumab, lenalidomide and dexamethasone for patient with POEMS syndrome: A case report" [Leukemia Research Reports (2024) Volume 22, 100491] [0.03%]
达雷妥尤单抗、来那度胺和地塞米松一线治疗POEMS综合征患者的疗效：病例报告的勘误(《白血病研究报道》(2024)卷22，100491)
E Amabile,F Fazio,M Martelli et al.
E Amabile et al.
[This corrects the article DOI: 10.1016/j.lrr.2024.100491.]. © 2025 The Authors.
Published Erratum
Leukemia research reports. 2025 Jan 20:23:100499. DOI:10.1016/j.lrr.2025.100499 2025